NCT03943706

Brief Summary

The FDA has shown clear interest in strategies that will reduce the public health burden of tobacco use. One proposed strategy includes banning the sale of fully nicotinized cigarettes and only allowing VLNCs (Very Low Nicotine Cigarettes) to be sold. While there are concerns regarding the unintended consequences (e.g., black market sales of fully nicotinized cigarettes) of such bans, research is needed to understand how smokers and dual users will act in the potential market. The overall aim of the current research is to understand purchasing and product choice behaviors of tobacco/nicotine users if the proposed ban were to go into effect.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jun 2019

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 7, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 9, 2019

Completed
23 days until next milestone

Study Start

First participant enrolled

June 1, 2019

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2019

Completed
Last Updated

December 19, 2020

Status Verified

December 1, 2020

Enrollment Period

6 months

First QC Date

May 7, 2019

Last Update Submit

December 16, 2020

Conditions

Keywords

e-cigarettesJUUL brand e-cigaretteNJOY brand e-cigaretteEVOLV brand mod e-cigaretteVery Low Nicotine Cigarettes (VLNCs)

Outcome Measures

Primary Outcomes (2)

  • Nicotine delivery measured by serum (blood) nicotine

    Participants will complete one standardized puffing bout (10 puffs) with each of the three electronic cigarettes, usual brand cigarette and Very Low Nicotine Cigarettes (VLNCs). Serum nicotine will be measured throughout each standardized puffing bout. Greater levels of serum nicotine will be indicative of greater nicotine delivery.

    1 month

  • Proportion of puffs earned and allocated to each product in three hypothetical tobacco regulatory scenarios

    Participants will complete three computer tasks simulating hypothetical regulatory scenarios and will earn and allocate puffs to study products. A greater proportion of puffs allocated will indicate greater demand for the product in that hypothetical scenario

    1 month

Study Arms (2)

Exclusive cigarette smokers

Exclusive cigarette smokers must smoke at least 10 cigarettes per day for the past three months and have exhaled carbon monoxide (eCO) levels of at least 6 ppm at the screening visit.

Dual (Electronic cigarette and cigarette smoking) users

Dual e-cigarette and cigarette users must have smoked at least 5 cigarettes per day for the last 3 months and use e-cigarettes at least 15 days per month for the last 3 months.

Eligibility Criteria

Age18 Years - 50 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

A sample of 40 current cigarette smokers (n=20) and dual e-cigarette and cigarette users (n=20) who are willing to use/try an alternative nicotine-delivery device will be recruited via advertisements/ recruitment materials (e.g., craigslist, ads on OSU, OU, and UCO campuses, OUHSC, email) and referrals. Participants will live in the Oklahoma City, OK metro area. Participants will be provided information about the study and provide initial consent for screening via an online screener.

You may qualify if:

  • be at least 18 years old
  • live within 30 miles of the research site
  • interested in/willing to use an e-cigarette during study visits
  • be willing and able to complete study procedures including specimen collection, survey completion, and remaining nicotine abstinent for 12 hours prior to each study visit
  • speak and understand English
  • willing to provide informed consent
  • bring usual brand cigarettes to screener study visit.
  • smoke at least 10 cigarettes per day for the past three months,
  • exhaled more than equal to 6 ppm carbon monoxide at the screener visit.
  • smoke more than equal to 5 tobacco cigarettes per day for the last 3 months,
  • use e-cigarettes at least 15 days per month for the last 3 months, and
  • bring e-cigarette device to screener study visit.

You may not qualify if:

  • currently suffering from lung disease including asthma, cystic fibrosis (CF), or chronic obstructive pulmonary disease (COPD), unless it is well-controlled,
  • currently pregnant or breast-feeding or have plans to become pregnant or begin breast-feeding at any point during the study,
  • intoxicated at study visits (breath alcohol testing and clean urine drug screen),
  • any known allergies or sensitivity to the known major constituents contained in the aerosol of the study e-cigarette devices (e.g., flavorants, vegetable glycerin, propylene glycol),
  • User of zero-nicotine e-cigarettes,
  • smokes mentholated cigarettes regularly,
  • history of cardiac event or distress within the past 3 months.
  • have previously used any e-cigarette device (cig-a-like, pen style, mod, APV) for longer than 30 days
  • use of an e-cigarette device over the past 14 days.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Oklahoma Health Sciences Center Oklahoma Tobacco Research Center

Oklahoma City, Oklahoma, 73104, United States

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

During their PK (Pharmacokinetics) visits, Blood will be collected during specific time points and plasma will be extracted from the blood. Plasma will be used to analyze the levels of nicotine in it. Urine will be collected from female participants in order to confirm their pregnancy status. Saliva will be collected during their screening visit to analyze for cotinine levels in order to check their smoking status.

MeSH Terms

Conditions

Tobacco UseVaping

Condition Hierarchy (Ancestors)

BehaviorSmoking

Study Officials

  • Theodore Wagener, PhD

    University of Oklahoma

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 7, 2019

First Posted

May 9, 2019

Study Start

June 1, 2019

Primary Completion

December 1, 2019

Study Completion

December 1, 2019

Last Updated

December 19, 2020

Record last verified: 2020-12

Locations